On June 27, 2024, the United States Supreme Court (the “Supreme Court” or “Court”) rendered a 5-4 opinion in Harrington v. Purdue Pharma, L.P. that “the [B]ankruptcy [C]ode does not authorize a release and injunction that, as...more
7/1/2024
/ Bankruptcy Code ,
Bankruptcy Court ,
Chapter 11 ,
Fraudulent Marketing ,
Non-Debtors ,
Opioid ,
Purdue Pharma ,
Reorganizations ,
SCOTUS ,
Third-Party ,
Unfair or Deceptive Trade Practices
On February 3, 2022, as part of a series of recent decisions addressing third-party releases, Bankruptcy Judge John T. Dorsey of the Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) confirmed the chapter...more
2/15/2022
/ Bankruptcy Court ,
Chapter 11 ,
Commercial Bankruptcy ,
Creditors ,
Debtors ,
Non-Consensual Rights ,
Opioid ,
Opt-Outs ,
Pharmaceutical Industry ,
Popular ,
Purdue Pharma ,
Third-Party
On December 16, 2021, in a significant decision, the United States District Court for the Southern District of New York (the “District Court”) vacated the order confirming the chapter 11 plan of Purdue Pharma L.P. (“Purdue”)...more
12/28/2021
/ Bankruptcy Code ,
Bankruptcy Court ,
Chapter 11 ,
Commercial Bankruptcy ,
Debtors ,
Non-Debtors ,
Opioid ,
OxyContin ,
Popular ,
Purdue Pharma ,
Statutory Authority